ValueScreener company report

Allogene Therapeutics, Inc. (ALLO)

Name: Allogene Therapeutics, Inc. (ALLO) filed financial figures
Creator: ValueScreener

NASDAQ / Healthcare / Biotechnology

Share price

1.34 USD Market dataClose of Oct 15, 2026

Market capitalisation

463.0M USD Market dataClose of Oct 15, 2026

Market data: Oct 15, 2026
Filed accounts: FY2025, filed Mar 12, 2026
Ratios computed: Oct 15, 2026
Filed years: 8, FY2018 to FY2025

Four kinds of sourceSEC filingCompany statementMarket dataComputedWhat each means

SEC filingFiled with the SEC: Read from a statement the company filed with the SEC, with the form, fiscal year, filing date and accession beside it.
Company statementCompany statement: What the company says about itself in a filing: an 8-K item, the auditor, its own segment names.
Market dataMarket data: Prices, market value and what analysts publish, with the date they are as of.
ComputedComputed by ValueScreener: Worked out by us from the other three, with the inputs and the formula one press away. A score is a research output, not a rating or a recommendation.

Reading

1 of 10

Overview

What the business is, what it costs, and how it reads on four questions.

Market dataSEC filingComputed

Quality

Return on equity

-65.3% Computed

From the FY2025 filing

Read quality

Financial strength

Current ratio

7.93 Computed

From the FY2025 filing

Read financial strength

Valuation

Price to earnings

n/m Computed

FY2025 accounts, priced at the latest close

Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

Read valuation

Cash generation

Free cash flow yield

n/a Computed

FY2025 accounts, priced at the latest close

Why n/a

Held back: the last annual report's share count does not match today's, as after a split.

Read cash generation

Revenue and net income, by fiscal year

Revenue Net income9 fiscal years; a year whose statement names no SEC filing is market data, and the table in Filings says which.

Named tests met: 0 of 30 Which tests

The business, and the score behind its five axes

The reading, in brief

Is it good

Return on equity was -65.2% in FY2025, in the band labelled "Likely below the cost of equity" (below 8.0%), on lines anchored on Damodaran's cost-of-capital data, suggesting returns on shareholders' money below the usual cost of equity.

Today, against the Biotechnology industry (494 companies), -65.2% sits at the 48th percentile; the middle half of that group runs from -146.9% to -28.9%.

Is it safe

Current ratio was 7.93 in FY2025, in the band labelled "At or above Graham's requirement" (2.00 and above), on lines anchored on Graham's defensive-investor criteria, suggesting short-term assets well above short-term obligations.

Today, against the Biotechnology industry (556 companies), 7.93 sits at the 69th percentile; the middle half of that group runs from 2.39 to 9.18.

Year by year against peers: Whether Allogene Therapeutics, Inc.'s return on equity stayed above the median of the Biotechnology industry, year by year. (FY2018 to FY2025, 8 fiscal years of Allogene Therapeutics, Inc. with a comparable figure)
The direction: Which way Allogene Therapeutics, Inc.'s return on equity has moved, and how steadily. (FY2018 to FY2025, 8 filed years of Allogene Therapeutics, Inc.)
What could explain it: What in Allogene Therapeutics, Inc.'s filed statements could explain the movements. (3 readings drawn from the statement lines Allogene Therapeutics, Inc. filed)
What to check next: What to check next on Allogene Therapeutics, Inc., and where in its filings. (2 questions for Allogene Therapeutics, Inc.)
In one paragraph: One paragraph on Allogene Therapeutics, Inc.'s returns, cash, balance sheet and price. (4 of sixteen figures read for Allogene Therapeutics, Inc.)

These are ALLO’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.

Research ALLOPart of Serious. New accounts start with 30 days of Professional, free, no card.

2 of 10

What changed

The newest filing, what it moved, and when the next one is due.

SEC filingCompany statement

The newest accounts on file are the FY2025 annual report: 10-K, filed Mar 12, 2026, accession 0001628280-26-017242.

3 of 10

Quality

The returns the business earns on its capital, and the margins behind them.

SEC filingComputed

Allogene Therapeutics, Inc: returns on capital and margins, each with its source
Figure	Value, source and document
Return on invested capital, after tax Why n/a The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.	n/a ComputedFY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
Return on equity	-65.3% ComputedFY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
Return on capital employed, pre-tax	-54.6% ComputedFY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
Return on assets	-45.9% ComputedFY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
Gross margin Why n/m This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.	n/m ComputedFY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
Operating margin Why n/m This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.	n/m ComputedFY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
Net margin Why n/m This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.	n/m ComputedFY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242

4 of 10

Financial strength

What it owes against what it owns, and whether it can meet what falls due.

SEC filingComputedCompany statement

Allogene Therapeutics, Inc: leverage, liquidity and distress, each with its source
Figure	Value, source and document
Debt to equity Why n/a The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.	n/a ComputedFY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
Current ratio	7.93 ComputedFY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
Quick ratio	7.93 ComputedFY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
Interest coverage Why n/m Operating income is zero or below, so there is no operating profit to cover the interest bill and coverage is not meaningful (n/m).	n/m ComputedFY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
Altman Z-score Why n/m This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.	n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
Net debt Why n/a The FY2025 balance sheet carries no net debt we could read.	n/a ComputedFY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242

Total assets Total liabilities Shareholders’ equity

The balance sheet, line by line

Financial health

What Allogene Therapeutics, Inc owned and owed at the end of fiscal 2025, from the balance sheet it filed (10-K, filed Mar 12, 2026, 0001628280-26-017242).

Allogene Therapeutics, Inc: balance sheet position
Total assets	415.9M FiledFY2025 10-K, filed Mar 12, 2026
Total liabilities	123.4M FiledFY2025 10-K, filed Mar 12, 2026
Shareholders' equity	292.5M FiledFY2025 10-K, filed Mar 12, 2026
Cash	258.3M FiledFY2025 10-K, filed Mar 12, 2026
Total debt	n/a FiledFY2025 10-K, filed Mar 12, 2026
Net debt	n/a
Current ratio	7.93
Debt to equity	n/a

Debt to equity: FY2025: The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
Interest cover: FY2025: Operating income is zero or below, so there is no operating profit to cover the interest bill and coverage is not meaningful (n/m).

Read from the filed balance sheet for each year, with the income statement of the same year supplying operating profit where a ratio needs it. Nothing here is a view on whether this company is sound.

5 of 10

Valuation context

What the market charges for it, against its own record and companies like it.

Market dataSEC filingComputed

Allogene Therapeutics, Inc: what the market charges, each with its source
Figure	Value, source and document
Price to earnings Why n/m Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.	n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
P/E on trailing twelve months	0.82x ComputedClose of Oct 15, 2026 · Trailing four quarters, each as known on the day; the quarterly filings are listed under Filings
Price to book Why n/a Held back: the last annual report's share count does not match today's, as after a split.	n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
Price to sales Why n/m This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.	n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
Enterprise value to EBIT Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
Enterprise value to EBITDA Why n/m EBITDA is zero or negative, so a multiple of it is not meaningful.	n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
Price to earnings over growth Why n/m Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.	n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
Diluted earnings per share	-0.87 USD FiledFY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
Graham number Why n/m Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.	n/m ComputedFY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242

We publish no fair value or price target of our own. Value ALLO on your own assumptions in the DCF workbench, starting from the filed figures.

Its own record, and companies like it

Valuation

What the market charges for Allogene Therapeutics, Inc today, and the multiples it has carried. No value of ours: the figures are the filings’ and the market’s.

Allogene Therapeutics, Inc: valuation
Share price	1.34 USD
Market capitalisation	463.0M USD
Enterprise value to EBITDA	n/m
Graham number	n/m
Diluted earnings per share, FY2025	-0.87 USD

Price to earnings on trailing twelve months, a different basis from the fiscal-year P/E above, since May 7, 2019: low 0.72x, median 0.77x, high 0.86x, latest 0.82x. 64 trading days with a meaningful ratio, 1,806 more on a loss and left out. Each close over the trailing twelve months of earnings as known that day: a quarter counts from the day it was filed.

Companies like Allogene Therapeutics, Inc

Same industry (Biotechnology) and size band (Small, 300M to 2B), nearest in market value and current ratio. Each of those counts equally, by how many of the companies considered sit between the two on it. Closest first: the order is likeness and nothing else.

6 of 10

Cash generation

Whether profit arrives as cash, and what is paid back to shareholders.

SEC filingComputed

Allogene Therapeutics, Inc: cash generation and what is paid out, each with its source
Figure	Value, source and document
Free cash flow yield Why n/a Held back: the last annual report's share count does not match today's, as after a split.	n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
Free cash flow	-149.6M USD ComputedFY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
Free cash flow margin Why n/m This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.	n/m ComputedFY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
Dividend yield Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
Payout ratio Why n/a We do not hold this figure for this company, so there is nothing to show.	n/a ComputedFY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242

Free cash flow Net incomeProfit that arrives as cash stands level with net income; a gap year after year is worth reading about.

7 of 10

Filings

Every figure, the year it is for and the document it was read from.

SEC filingMarket data

The filed figures

Computed from the accounts this company filed with the SEC and, in a ratio with a price in it, the last close, dated on this page. Every filed figure below carries the fiscal year and the filing date its accounts were read from, and every blank carries the reason it is blank. Nothing here is a view on this company.

Allogene Therapeutics, Inc.: the eight ratios, with the fiscal year and filing date behind each.
Figure	Value	Year	As of
	n/m	FY2025	Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
FormulaShare price / earnings per share. Where the filing states no earnings per share this listing can be priced on, which is every 20-F and 40-F filer because theirs is stated per ordinary share, it is market capitalisation / net income: the same multiple, undiluted. As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form10-KFiledMar 12, 2026PeriodFY2025Accession0001628280-26-017242What we read from itIncome statementFY2025Open on SEC.gov, accession 0001628280-26-017242, leaves this page and opens in a new tab
	n/a	FY2025	Oct 15, 2026
n/a Held back: the last annual report's share count does not match today's, as after a split.
FormulaMarket capitalisation / shareholders equity As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form10-KFiledMar 12, 2026PeriodFY2025Accession0001628280-26-017242What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001628280-26-017242, leaves this page and opens in a new tab
	n/a	FY2025	Oct 15, 2026
n/a Operating profit is zero or negative, so there is no profit for a buyer's price to be a multiple of.
Formula(Market capitalisation + total debt - cash) / operating income, or over the filing's own EBIT (income before tax + interest expense) where the filer tags no operating line, as Johnson & Johnson does not in any of its ten filed years. As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form10-KFiledMar 12, 2026PeriodFY2025Accession0001628280-26-017242What we read from itIncome statementFY2025Open on SEC.gov, accession 0001628280-26-017242, leaves this page and opens in a new tabForm10-KFiledMar 12, 2026PeriodFY2025Accession0001628280-26-017242What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001628280-26-017242, leaves this page and opens in a new tab
	n/a	FY2025	Oct 15, 2026
n/a Held back: the last annual report's share count does not match today's, as after a split.
FormulaFree cash flow per share / share price x 100 As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form10-KFiledMar 12, 2026PeriodFY2025Accession0001628280-26-017242What we read from itCash flow statementFY2025Open on SEC.gov, accession 0001628280-26-017242, leaves this page and opens in a new tab
	n/a	FY2025	Mar 12, 2026
n/a The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
FormulaVendor trailing-twelve-month return on invested capital where one is published, which uses after-tax operating profit over total assets less current liabilities. Otherwise our own recompute: NOPAT / (shareholders equity + total debt - cash) x 100, where NOPAT is the filed operating profit after tax, or the filing's own EBIT after tax where the filer tags no operating line. As ofThe filing date of the statements below, for FY2025. Form10-KFiledMar 12, 2026PeriodFY2025Accession0001628280-26-017242What we read from itIncome statementFY2025Open on SEC.gov, accession 0001628280-26-017242, leaves this page and opens in a new tabForm10-KFiledMar 12, 2026PeriodFY2025Accession0001628280-26-017242What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001628280-26-017242, leaves this page and opens in a new tab
	n/a	FY2025	Oct 15, 2026
n/a The filed cash flow statement reports no dividend paid at all. That is not the same as a filed zero, and we will not read it as one.
FormulaCommon dividends paid in the latest filed year / market capitalisation x 100. n/a where the filing cannot support it: a special or first-year payment, a total that mixes preferred dividends, or a cash-flow statement over 15 months old. As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form10-KFiledMar 12, 2026PeriodFY2025Accession0001628280-26-017242What we read from itCash flow statementFY2025Open on SEC.gov, accession 0001628280-26-017242, leaves this page and opens in a new tab
	n/a	FY2025	Mar 12, 2026
n/a The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
FormulaTotal debt / shareholders equity As ofThe filing date of the statements below, for FY2025. Form10-KFiledMar 12, 2026PeriodFY2025Accession0001628280-26-017242What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001628280-26-017242, leaves this page and opens in a new tab
	7.93	FY2025	Mar 12, 2026
FormulaCurrent assets / current liabilities As ofThe filing date of the statements below, for FY2025. Form10-KFiledMar 12, 2026PeriodFY2025Accession0001628280-26-017242What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001628280-26-017242, leaves this page and opens in a new tab
	n/m	FY2025	Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
FormulaMarket capitalisation / revenue As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form10-KFiledMar 12, 2026PeriodFY2025Accession0001628280-26-017242What we read from itIncome statementFY2025Open on SEC.gov, accession 0001628280-26-017242, leaves this page and opens in a new tab
	n/m	FY2025	Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
FormulaPrice to earnings / the annual earnings growth rate, in percentage points As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form10-KFiledMar 12, 2026PeriodFY2025Accession0001628280-26-017242What we read from itIncome statementFY2025Open on SEC.gov, accession 0001628280-26-017242, leaves this page and opens in a new tab
	n/m	FY2025	Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
Formula1.2 x working capital/assets + 1.4 x retained earnings/assets + 3.3 x EBIT/assets + 0.6 x market value of equity/total liabilities + 1.0 x revenue/assets As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form10-KFiledMar 12, 2026PeriodFY2025Accession0001628280-26-017242What we read from itIncome statementFY2025Open on SEC.gov, accession 0001628280-26-017242, leaves this page and opens in a new tabForm10-KFiledMar 12, 2026PeriodFY2025Accession0001628280-26-017242What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001628280-26-017242, leaves this page and opens in a new tab
	n/m	FY2025	Mar 12, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
FormulaAn eight-variable index of year-on-year changes in receivables, gross margin, asset quality, revenue, depreciation, overheads, leverage and accruals As ofThe filing date of the statements below, for FY2025. Form10-KFiledMar 12, 2026PeriodFY2025Accession0001628280-26-017242What we read from itIncome statementFY2025Open on SEC.gov, accession 0001628280-26-017242, leaves this page and opens in a new tabForm10-KFiledMar 12, 2026PeriodFY2025Accession0001628280-26-017242What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001628280-26-017242, leaves this page and opens in a new tabForm10-KFiledMar 12, 2026PeriodFY2025Accession0001628280-26-017242What we read from itCash flow statementFY2025Open on SEC.gov, accession 0001628280-26-017242, leaves this page and opens in a new tab
	n/m	FY2025	Mar 12, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
FormulaOne point each for: positive return on assets, positive operating cash flow, rising return on assets, operating cash flow above net income, falling leverage, rising current ratio, no new shares issued, rising gross margin, rising asset turnover. As ofThe filing date of the statements below, for FY2025. Form10-KFiledMar 12, 2026PeriodFY2025Accession0001628280-26-017242What we read from itIncome statementFY2025Open on SEC.gov, accession 0001628280-26-017242, leaves this page and opens in a new tabForm10-KFiledMar 12, 2026PeriodFY2025Accession0001628280-26-017242What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001628280-26-017242, leaves this page and opens in a new tabForm10-KFiledMar 12, 2026PeriodFY2025Accession0001628280-26-017242What we read from itCash flow statementFY2025Open on SEC.gov, accession 0001628280-26-017242, leaves this page and opens in a new tab

The figures are computed from the accounts for fiscal 2025, the newest full year on file. 8 filed fiscal years on record, FY2018 to FY2025, from SEC EDGAR. Prices as of Oct 15, 2026. Ratios recomputed Oct 15, 2026. Two facts, because a recompute is not a fresh quote.

The year and the filing date name the statement each figure’s accounts are read from, and they stand even where the figure itself could not be computed: the line beneath a blank says what that statement did not carry. A figure’s name opens its formula and the filings behind it; a statement that names no SEC filing has no filing date, and reads n/a.

Ten years of filed figures, year by year

Ten years of filed figures

9 fiscal years, FY2017 to FY2025. 8 read from the annual reports Allogene Therapeutics, Inc filed with the SEC, each naming its filing; the rest from statements that name none, which are market data. Amounts in USD, as reported.

Allogene Therapeutics, Inc: revenue, earnings, free cash flow and returns, by fiscal year, with the filing each year was read from
Year	Revenue	Operating income	Net income	EPS, diluted	Free cash flow	Operating margin	Return on equity	Filing
FY2025	0.00	-209.3M	-190.9M	-0.87	-149.6M	n/m	-65.3%	10-K, Mar 12, 20260001628280-26-017242
FY2024	22.0K	-273.2M	-257.6M	-1.32	-201.0M	-1241813.6%	-61.0%	10-K, Mar 13, 20250001737287-25-000036
FY2023	95.0K	-327.7M	-327.3M	-2.09	-239.2M	-344986.3%	-63.9%	10-K, Mar 14, 20240001737287-24-000021
FY2022	156.0K	-335.5M	-340.4M	-2.38	-225.7M	-215087.2%	-51.0%	10-K, Feb 28, 20230001737287-23-000018
FY2021	114.1M	-180.2M	-182.1M	-1.34	-206.3M	-157.9%	-19.7%	10-K, Feb 23, 20220001737287-22-000013
FY2020	0.00	-258.2M	-316.4M	-2.63	-181.1M	n/m	-31.2%	10-K, Feb 25, 20210001737287-21-000009
FY2019	0.00	-202.0M	-184.6M	-1.83	-188.1M	n/m	-29.4%	10-K, Feb 27, 20200001737287-20-000012
FY2018	n/a	-192.8M	-211.5M	-7.31	-47.9M	n/a	-30.1%	10-K, Mar 8, 20190001564590-19-006991
FY2017	n/a	-2.0K	-2.0K	-0.00	n/a	n/a	n/m	Market data, supplied Oct 15, 2026accession n/a

Revenue: Revenue was not positive in both 2019 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
Earnings: Earnings was not positive in both 2017 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
Earnings per share: Earnings per share was not positive in both 2017 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
Free cash flow: Free cash flow was not positive in both 2018 and 2025, so a compound rate across the window is not defined. Both figures are in the table.

Every figure in this section is a line of a filed annual statement or a ratio of two of them. Nothing here is estimated or smoothed. Earnings per share filed before a share split are put on today's share count, and say so. Nothing here is a verdict on the company.

8 of 10

Risks and guardrails

The accounting screens, the published tests, and the lines you can set to be told.

ComputedCompany statement

Allogene Therapeutics, Inc: accounting screens and published tests, each with its source
Figure	Value, source and document
Beneish M-score Why n/m This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.	n/m ComputedFY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
Piotroski F-score Why n/m This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.	n/m ComputedFY2025 10-K, filed Mar 12, 2026, 0001628280-26-017242
Named tests met	0 of 30 Computed
Beta	1.61 ComputedClose of Oct 15, 2026

The named tests

Of 30 tests value investors published: 0 met, 17 not met, 13 we could not complete. Counts, never a score: a single figure would have to decide that meeting one investor’s criteria and meeting another’s are worth the same.

Which tests, by name(all 30)

Meets: None of the named tests.
Does not: Defensive investor (Benjamin Graham); Deep value; Large cap, low P/E; High F-score, low P/B (Joseph Piotroski); High returns and growth; High yield, low payout; Dividends and buybacks; Low beta, profitable; Near the 52-week low; Two thirds of NCAV (Benjamin Graham); High returns, low debt; Owner earnings yield; High return on tangibles; Book or below, low debt (Walter Schloss); Tangible book or below; Cash-flow yield and ROIC; Cheapest quarter on P/B (David Dreman)
Not measured: Earnings yield and ROIC (Joel Greenblatt); Three forensic scores; Low PEG, low debt (Peter Lynch); Gross margin, turnover (Robert Novy-Marx); EV/EBITDA and coverage; ROIC at or above WACC; Z-score and coverage (Edward Altman); P/E times P/B (Benjamin Graham); Low P/S, rising earnings (James O'Shaughnessy); Cash-covered dividend; Clean books, high ROIC; Cheapest quarter on P/E (David Dreman); Low P/E, growth, yield (John Neff). A test with a figure we could not read is incomplete, never met and never failed.

Figures we could not read(21)

Debt to Equity: The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
Piotroski F-Score: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
P/E Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
EV/EBIT: We do not hold this figure for this company, so there is nothing to show.
Return on Invested Capital: The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
Altman Z-Score: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
Beneish M-Score: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
PEG Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
Eps Growth 5Y: We do not hold this figure for this company, so there is nothing to show.
Rev Growth 5Y: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
Gross Margin: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
Asset Turnover: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
EV/EBITDA: EBITDA is zero or negative, so a multiple of it is not meaningful.
Interest Coverage: Operating income is zero or below, so there is no operating profit to cover the interest bill and coverage is not meaningful (n/m).
Dividend Yield: We do not hold this figure for this company, so there is nothing to show.
Payout Ratio: We do not hold this figure for this company, so there is nothing to show.
ROIC-WACC Spread: We do not hold this figure for this company, so there is nothing to show.
Price To Graham: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
P/S Ratio: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
Dividend Coverage Ratio: We do not hold this figure for this company, so there is nothing to show.
Dividend Streak: We do not hold this figure for this company, so there is nothing to show.

9 of 10

Declared positions

Whether anybody here owns this company.

Positions declared by Javier Sanz Alvarez: no holding in any company shown here, as of October 3, 2026.

10 of 10

Next step

What to do with what you have read.

Value it in the DCF workbench

A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.

What this cannot tell you

21 figures could not be read on this company, among them Debt to Equity, Piotroski F-Score, P/E Ratio. Each blank in the table above names the rest, with its reason. 13 named tests come back incomplete because of them, which is neither met nor missed.
We hold 8 filed fiscal years rather than 10, so the run above is shorter than a full decade and is counted as what it is.

And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.

Running this once is arithmetic on public documents and you are welcome to it. Writing down why you own each company, in your own words and with the numbers that have to stay true for it to hold, and then having those numbers re-checked every night against the newest filed accounts, and against the latest close where a rule watches a price, is Professional, the plan a new account starts on for 30 days, one trial per person. It writes to you the day one breaks, and stays quiet when nothing does. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published.

Monitor my portfolio How this is computed

No card. 30 free days, and nothing is charged unless you choose a plan.

Analyze your own portfolio

ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.

A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.

Four questions, at a glance

Quality

Financial strength

Valuation

Cash generation

Revenue and net income, by fiscal year

The reading, in brief

Financial health

Valuation

Companies like Allogene Therapeutics, Inc

The filed figures

Ten years of filed figures

The named tests

What this cannot tell you

Margin Notes